Guide-Extension Catheter–Assisted Bail-Out Thrombus Aspiration During PCI for Thrombus-Rich Acute Coronary Syndromes: Contemporary Review and Clinical Case Examples

1. Introduction

Large intracoronary thrombus burden during acute coronary syndrome (ACS) increases the risk of distal embolization, microvascular obstruction, no-reflow or slow-flow, larger infarct size, impaired myocardial recovery, and adverse clinical outcomes [1,2,3,4]. Early enthusiasm for manual aspiration was driven by studies such as TAPAS and EXPIRA, in which aspiration with the Export catheter or similar manual systems improved surrogate markers of reperfusion and infarct size [5,6]. However, larger randomized trials subsequently failed to confirm a hard-outcome benefit of routine aspiration and raised concern regarding stroke, particularly in the TOTAL trial [7,8,9]. Accordingly, contemporary European and North American guidelines discourage routine aspiration thrombectomy and reserve thrombus-removal strategies for selected bail-out situations [10,11].

Despite negative randomized evidence for routine manual aspiration, thrombus-rich ACS remains a daily procedural problem. Selective thrombus removal may still be necessary when conventional balloon angioplasty or direct stenting cannot be performed safely in a large thrombotic mass, when distal embolization or no-reflow occurs, or when thrombus persists despite antithrombotic therapy. Contemporary options include conventional manual aspiration catheters, sustained mechanical aspiration systems such as the Indigo CAT RX platform, and stent-retriever-based coronary thrombectomy technologies such as NeVa and enVast [12,13,14,15,16].

Guide-extension catheters (GECs), including GuideLiner, Guidezilla, Telescope, LiquID, and similar devices, are widely used to improve guide-catheter support, coaxiality, and device delivery during complex PCI. Because of their relatively large inner lumen and deliverability into proximal or mid-coronary segments, GECs may also permit retrieval of bulky thrombus in selected bail-out scenarios. A key early feasibility experience was reported by Farooq et al., who applied a combined “forward” and “back” aspiration strategy in 30 consecutive STEMI procedures, including bail-out GuideLiner-assisted aspiration in nine patients after conventional aspiration was inadequate [17]. This off-label application has otherwise been described mainly in small series and case reports and remains unsupported by prospective comparative data [18,19,20,21,22,23,24,25].

Why this topic matters now is that the procedural landscape has evolved while real-world device availability remains variable. Dedicated aspiration and thrombectomy technologies are increasingly described and, in some cases, formally evaluated, but many catheterization laboratories may not have immediate access to these platforms in time-critical ACS procedures. A practical review of GEC-assisted aspiration as an off-label contingency technique may therefore be useful for operators facing refractory thrombus during percutaneous coronary intervention (PCI), provided that the technique is framed conservatively and not presented as a validated alternative to dedicated thrombectomy systems.

Because no dedicated consensus document specifically addresses GEC-assisted coronary thrombus aspiration, procedural decisions should be individualized and grounded in contemporary ACS guidance, device availability, thrombus morphology, coronary anatomy, and operator experience.

2. Literature Search Strategy

This manuscript is framed as a contemporary narrative review with practical clinical case examples. PubMed/MEDLINE and Google Scholar were searched from inception through May 2026 using combinations of “guide extension catheter”, “mother-and-child”, “Guidezilla”, “GuideLiner”, “Telescope”, “LiquID”, “Export”, “manual aspiration catheter”, “thrombus aspiration”, “thrombectomy”, “no-reflow”, “slow-flow”, “CAT RX”, “CHEETAH”, “NeVa”, “enVast”, “stent retriever”, “continuous aspiration”, “forward aspiration”, and “back aspiration”. Guideline statements, randomized thrombectomy trials, device-specific studies, nonrandomized feasibility studies, small series, and case reports were screened. The evidence base for GEC-assisted aspiration remains limited to nonrandomized feasibility data, small series, and case reports.

3. Clinical Case Examples

Appendix A presents six clinical examples from real-world practice. Cases were selected retrospectively from thrombus-rich PCI procedures in which GEC-assisted aspiration was used as a bail-out maneuver after conventional thrombus-management strategies were inadequate, unavailable, unsuitable, or technically unsuccessful. Clinical, angiographic, procedural, and immediate in-hospital outcomes were extracted from procedural records. Thrombus burden, flow restoration, no-reflow or slow-flow, distal embolization, and immediate complications were assessed by operator review. No independent angiographic core laboratory, systematic neurologic assessment, or prespecified follow-up protocol was used.

The case examples are intentionally described as illustrative rather than representative. All patients were male; five of six procedures involved the right coronary artery; and the clinical contexts were heterogeneous. Four cases most closely matched the thrombus-rich ACS bail-out scenario, whereas Case 5 (subacute stent-edge thrombus in unstable angina) and Case 6 (post-stenting thrombus shift) are retained only as adjacent technical examples demonstrating thrombus retrieval mechanics. Table 1 presents the case examples in a procedural format, including patient age, presentation, culprit vessel, baseline TIMI flow, thrombus grade, failed prior strategy, GEC used, number of aspiration passes, adjunctive pharmacology, intracoronary imaging, final TIMI flow, no-reflow or distal embolization, and in-hospital adverse events. Because of the small sample size, lack of a control group, and selection bias, no inference can be made regarding procedural success rates, stroke risk, mortality, or comparative performance against dedicated aspiration or thrombectomy systems. The observation that no immediate complication occurred is descriptive only and should not be interpreted as a safety claim.

4. Patient Selection: Potential Bail-Out Scenarios and Situations to Avoid

GEC-assisted aspiration may be considered only as a bail-out option in selected thrombus-rich ACS procedures. Potential scenarios include persistent TIMI thrombus grade 4-5 (Figure 1) with impaired epicardial flow despite wiring and antithrombotic therapy, failure or inadequacy of a dedicated aspiration catheter to capture bulky thrombus, inability to access a purpose-built aspiration or mechanical thrombectomy system in a time-critical scenario, or thrombus visibly lodged at the mouth of a catheter that cannot be retrieved safely by conventional means.

This framework is a feasible pathway based on limited clinical experience and should not be interpreted as a guideline recommendation.

GEC-assisted aspiration should generally be avoided or abandoned in small vessels (<2.5 mm), severe ostial disease, long diffusely diseased segments, marked vessel tortuosity, pressure damping, poor guide coaxiality, inability to maintain therapeutic anticoagulation, or whenever deep intubation appears likely to cause vessel injury. Additional caution is warranted in cardiogenic shock or severe left ventricular dysfunction, in which prolonged manipulation, transient pressure damping, or distal embolization may be poorly tolerated by the patient. If a dedicated thrombectomy technology with supportive clinical evaluation is available, deliverable, and suitable for the anatomy

5. Contemporary Thrombectomy Device Landscape

Conventional manual aspiration catheters remain the historical comparator. The Export catheter was prominently studied in TAPAS and EXPIRA, which supported feasibility and improved reperfusion surrogates, but these single-center and mechanistic data were subsequently outweighed by large randomized evidence showing no routine clinical benefit and a significantly increased stroke signal with systematic aspiration [5,6,7,8,9]. Therefore, failure of an Export-type catheter in an individual case does not establish the superiority of a GEC. Rather, it identifies a practical problem in which alternative thrombus-management strategies may be considered.

Sustained and continuous mechanical aspiration represents a more contemporary approach. The Indigo CAT RX system is a purpose-built aspiration platform designed for continuous mechanical aspiration of coronary thrombus. In A Prospective, Multicenter Study to Evaluate the Safety and Performance of the CAT RX Aspiration Catheter in Patients With a High Thrombus Burden Acute Coronary Vessel Occlusion (CHEETAH), sustained aspiration performed before PCI was associated with high rates of final TIMI 3 flow, myocardial blush grade 3, and successful thrombus removal, with no device-related serious adverse events reported [12]. Although CHEETAH was not a randomized comparison against PCI alone or against GEC-assisted aspiration, it provided a stronger device-specific clinical evidence base than case-level GEC experience.

Stent-retriever-based coronary thrombectomy is another emerging strategy adapted from neurovascular and neuroradiology thrombectomy principles. In a prospective first-in-human EuroIntervention experience, the NeVa mechanical thrombectomy device was used in ACS patients with large thrombus burden, providing structured device-specific feasibility and safety data [13]. EnVast has also been reported as a bail-out mechanical thrombectomy system after conventional thrombus aspiration failure in STEMI with massive thrombotic burden [14]. More recently, EuroIntervention published a 2026 case report describing stent retriever-assisted coronary thrombectomy with continuous aspiration, further supporting the concept that combined retrieval and aspiration may be technically feasible in selected refractory coronary thrombus scenarios [15].

Taken together, device selection should be individualized and should reflect thrombus morphology, coronary anatomy, deliverability, local availability, and operator experience. Manual thrombus aspiration catheters are familiar and simple but have limited support for routine PCI use. CAT RX provides sustained aspiration with prospective multicenter data. Stent-retriever-based systems such as NeVa and enVast are specifically engineered for clot engagement and retrieval and are being evaluated more systematically. Where dedicated thrombectomy systems are available, deliverable, and appropriate for the anatomy, they should be considered within the operator’s thrombus-management strategy because they have more device-specific evaluation than off-label GEC-assisted aspiration. However, no randomized comparison exists between these technologies and GEC-assisted aspiration. Based on our limited clinical experience, GEC-assisted thrombus aspiration may remain useful when dedicated thrombus removal devices fail, are unavailable, cannot be advanced, or when a GEC is already positioned near a large proximal thrombus and can be used without unsafe deep intubation. However, its evidence base for this indication is limited and should be acknowledged as such.

The mechanistic rationale for GEC-assisted aspiration is based on three features: a larger effective aspiration lumen compared with many conventional manual aspiration catheters, improved coaxial engagement of proximal thrombus, and the ability to retrieve thrombus en bloc when thrombus is lodged at the catheter tip. These features may be particularly relevant for bulky proximal thrombus, organized thrombus, or thrombus with structural features that limit capture by smaller aspiration catheters [26,27]. Conversely, these same features increase the importance of careful vessel selection, avoidance of forceful deep intubation, and uninterrupted negative pressure during withdrawal.

6. Technique Description for Selective GEC-Assisted Thromboaspiration

The following steps represent technical considerations from a single-center experience rather than a validated procedural algorithm, as shown in Figure 2.

1. Initial preparation: Cross the lesion with a suitable coronary wire and optimize guide-catheter coaxiality. Consider microcatheter support when wiring is difficult. Deep intubation should not be attempted if the guide is non-coaxial, if pressure damping occurs, or if there is significant ostial disease or severe tortuosity.

2. GEC positioning: Advance the GEC gently over the wire to a position just proximal to the thrombus. Balloon anchoring or inchworm techniques may be considered only when necessary and only if they can be performed without excessive vessel trauma. Resistance should prompt reassessment rather than forceful advancement. Device-specific knowledge is required while relevant specifications of commonly used GEC devices are summarized in Table 2.

3. Establish uninterrupted suction and negative pressure: The aspiration system must be fully de-aired. A 20- to 60-mL Luer-lock/VacLok syringe or equivalent suction source can be connected through a stopcock on the side-port of the Y-connector. Once thrombus aspiration starts, negative pressure should not be released while the GEC is engaged with thrombus, because loss of suction may promote distal or systemic embolization.

4. Thrombus retrieval: Short, controlled forward/back movements may help engage thrombus at the GEC tip. If the tip becomes corked, the GEC should be withdrawn slowly under continuous negative pressure, preferably with the system removed en bloc and flushed outside the patient body. The guiding catheter should be meticulously aspirated/back-bled before further device delivery. The aspiration and flushing management is a crucial part of the GEC use in order to minimize risk of embolization of thrombotic debris and remnants that might be present in the system.

5. Adjunctive measures: Vasodilators or other pharmacologic agents may be used for slow-flow/no-reflow according to local practice and bleeding risk. GP IIb/IIIa inhibitors may be considered for bail-out thrombotic complications according to guideline-supported rescue use [10,11]. Types of pharmacological agents that might be administered to a patient with appropriate dosages and potential adverse events are described in Table 3.

Intracoronary imaging with IVUS or OCT may be considered after restoration of flow to define mechanism, lesion morphology, stent apposition/expansion, and the need for definitive treatment. This should not be framed as mandatory, because evidence supporting its use specifically after GEC-assisted thrombus aspiration is lacking.

7. Distal Embolization Protection, “Balloon-Block” Technique, and Local Intraprocedural Pharmacology

Distal protection filters, distal balloon “block” techniques, and combined aspiration/pharmacologic approaches should be described as occasional case-based adjuncts, not as routine components of a structured pathway. Their use may be rational in selected large-vessel or ectatic vessel anatomy, but evidence is limited and current guidelines do not explicitly endorse these maneuvers for GEC-assisted aspiration [28,29].

Farooq et al. prospectively evaluated a combined “forward” and “back” aspiration strategy in 30 consecutive STEMI procedures. Forward aspiration used a conventional aspiration catheter, with bail-out GuideLiner aspiration—with or without a distally inflated balloon—when thrombus persisted; back aspiration applied negative pressure through a GuideLiner or deeply intubated guide catheter during balloon deflation and stent optimization. GuideLiner-assisted bail-out aspiration was used in 9/30 cases and back aspiration in all 30. Although angiographic flow and blush were generally maintained, distal embolization to an unprotected branch and longitudinal stent deformation were reported. These findings support technical feasibility but not routine efficacy or safety [17].

Randomized and mechanistic studies of intracoronary low-dose fibrinolysis during STEMI have not provided a consistent clinical benefit, while full-dose facilitated PCI with systemic fibrinolysis is a distinct and harmful strategy that should not be conflated with very low-dose local intracoronary administration [30,31,32,33,34,35]. If low-dose intracoronary fibrinolytic therapy is contemplated by the operator, it should be regarded as off-label, highly selected, and subordinate to bleeding risk and institutional practice rather than presented as a recommendation [36,37,38,39].

8. Safety Considerations

Potential complications of GEC-assisted aspiration include vessel dissection, pressure damping and ischemia during deep seating, distal embolization/no-reflow, systemic embolization if thrombus is released during withdrawal, guide or GEC thrombosis, air embolism, and device-delivery-specific complications such as stent stripping at the GEC collar [40,41]. The stroke signal observed with routine manual aspiration in TOTAL trial cannot be directly extrapolated to selective GEC use, but it should heighten vigilance regarding aspiration mechanics, uninterrupted suction, guide aspiration/back-bleeding, and periprocedural neurologic surveillance [8,9]. Guide catheter extension can also induce a longitudinal stent deformation (LSD) by mechanically exerting force on the freshly implanted stent as it collides with the proximal part of the stent.

The illustrative case series presented in this manuscript is inadequate to estimate the incidence of stroke or other infrequent complications. For a zero-event series of six patients, the confidence interval around any rare-event rate is too wide to support reassurance. Therefore, the absence of observed complications remains descriptive only. Potential pitfalls and complications of the proposed GEC-assisted thrombus aspiration, with preventive and management measures are shown in Table 4.

9. Discussion

Based on available data and our clinical experience, GEC-assisted thrombus aspiration should be positioned as a selective and narrowly indicated bail-out maneuver rather than a review-derived clinical algorithm. The technique may have value in selected scenarios because a GEC can be advanced coaxially to the thrombus face and may provide a larger lumen than some conventional manual aspiration catheters. However, the evidence supporting this approach comprises one prospective nonrandomized feasibility study, small series, and case reports, and the technique should not be generalized beyond carefully selected anatomy and experienced operators [17,18,19,20,21,22,23,24,25].

A central practical message is that GEC use must be interpreted within, not isolated from, the evolving thrombectomy landscape. Export-type manual aspiration catheters are historically important but insufficient as the only comparator. CAT RX continuous mechanical aspiration has prospective multicenter evidence in high-thrombus-burden ACS, while NeVa/enVast and related stent-retriever plus aspiration strategies are purpose-built technologies with emerging EuroIntervention and JACC Cardiovascular Interventions experience and ongoing randomized evaluation [5,6,12,13,14,15,16].

Where dedicated thrombectomy systems are available, deliverable, and appropriate for the anatomy, they should be considered within the operator’s thrombus-management strategy because they have more device-specific evaluation than off-label GEC-assisted aspiration. However, no randomized comparison exists between these technologies and GEC-assisted aspiration. Conversely, GEC-assisted aspiration may remain relevant when dedicated devices fail, are unavailable, cannot be advanced, or when a GEC is already positioned near a large proximal thrombus and can be used without unsafe deep intubation. This should be viewed as a contingency pathway rather than a competing device strategy.

The case series illustrates feasibility in selected thrombus-rich procedures, particularly in large RCA anatomy. It does not establish efficacy, safety, or generalizability to LAD, left main, circumflex, small-vessel, cardiogenic shock, or severe LV dysfunction scenarios. This is particularly important because distal embolization in the LAD territory with specific anatomical nuances of the LAD may have different clinical consequences than in the RCA. The heterogeneous cases also require cautious interpretation. Case 5 and Case 6 are retained only as adjunctive technical examples. Of note, Case 5 represents subacute stent-edge thrombus in unstable angina rather than the primary STEMI/high-thrombus-burden paradigm while Case 6 represents thrombus shift after stent implantation rather than a primary refractory thrombotic occlusion. These examples should not be used to justify a broad indication or a management algorithm.

Future scientific work should prioritize prospective registries capturing coronary anatomy, thrombus grade, device availability, aspiration approach, number of passes, use of adjunctive pharmacology, intracoronary imaging, neurologic outcomes, distal embolization/no-reflow, and comparative performance against modern dedicated systems. The question of the potential role of GEC-assisted thrombus aspiration as a frontline approach, prior to primary PCI, rather than as a bailout treatment remains open and should be a subject of future research efforts. In general, until data showing that GEC-assisted thrombus aspiration improves clinical outcomes are available, this approach should remain selective, protocolized, and explicitly bailout-oriented. It may be combined with adjunct pharmacological measures, as summarized in the Figure 3.

10. Limitations

There are notable limitations to this work. It is a review article supported by retrospective, single-center clinical case examples, and the case component is small, uncontrolled, and subject to selection and publication bias. The literature search was narrative rather than systematic, with no protocol, duplicate screening, or formal risk-of-bias assessment. All patients were male and most cases involved the right coronary artery. The procedural scenarios were heterogeneous, and two cases were adjacent technical examples rather than representative primary PCI bail-out cases. Follow-up was limited, and no systematic neurologic assessment or independent angiographic core-laboratory review was performed. The manuscript should therefore be interpreted as a technical review with hypothesis-generating clinical illustrations, not as evidence of efficacy or safety.

11. Conclusions

GEC-assisted thrombus aspiration may be feasible as a selective bail-out maneuver for thrombus-rich ACS when conventional measures fail or dedicated thrombectomy systems are unavailable, unsuitable, or unsuccessful. It should not be used routinely and should not be represented as a guideline-supported or validated thrombectomy strategy. Any use requires meticulous aspiration mechanics, careful anatomy selection, strict anticoagulation and de-airing discipline, and conservative interpretation of procedural success. Larger prospective datasets are required before efficacy, safety, or comparative value can be assessed.